Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder

INTRODUCTION: Cannabis use disorder (CUD) is prevalent in ~2–5% of adults in the United States and is anticipated to increase as restrictions to cannabis decrease and tetrahydrocannabinol (THC) content in cannabis products increase. No FDA-approved medications for CUD are currently available, despit...

Descripción completa

Detalles Bibliográficos
Autores principales: Phan, Angela N., Terry, Garth E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Psychiatry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10330760/
https://www.ncbi.nlm.nih.gov/pubmed/37435402
http://dx.doi.org/10.3389/fpsyt.2023.1144276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10330760/
https://www.ncbi.nlm.nih.gov/pubmed/37435402
http://dx.doi.org/10.3389/fpsyt.2023.1144276

Ejemplares similares